The clinical trial process is a long, expensive, complicated one that often ends in failure. This means that to have a successful outcome, careful decision making and planning are absolutely essential ...
AUSTIN, Texas--(BUSINESS WIRE)--CDISC is proud to announce a research collaboration with the U.S. Food and Drug Administration’s Office of Translational Sciences in the Center for Drug Evaluation and ...
AUSTIN, Texas--(BUSINESS WIRE)--July 11, 2006--On Wednesday, 21 June 2006, Janet Woodcock, FDA Deputy Commissioner for Operations and Chief Operating Officer, announced during her DIA presentation, ...
One key goal of this initiative is to facilitate the participation of investigators and investigative site personnel in clinical trials by allowing them to enter data in a common format across trials.
TUCSON, Ariz., and AUSTIN, Texas - June 13, 2017 - The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the availability of a Duchenne muscular ...
CDISC and the National Organization forRare Disorders (NORD(R)) have announced a partnership to develop global data standards for rare diseases. The data standards will be released in a Therapeutic ...
As always, CDISC begins the year with a flurry of activity (do keep an eye on the website for regular updates and news on the standards). In addition to the CDISC standards themselves, the CDISC Board ...
The clinical trial process is a long, expensive, complicated one that often ends in failure. This means that to have a successful outcome, careful decision making and planning are absolutely essential ...
TUCSON, Ariz. & AUSTIN, Texas--(BUSINESS WIRE)--The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the availability of a Duchenne muscular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback